Literature DB >> 18707872

The First European Conference on Infections in Leukaemia - ECIL1: a current perspective.

Françoise Meunier1, Colette Lukan.   

Abstract

The First European Conference on Infections in Leukaemia - ECIL1 - was organised under the auspices of the Infectious Diseases Group of the European Organisation for Research and Treatment of Cancer (EORTC), the Infectious Diseases Working Party of the European Group for Blood and Bone Marrow Transplantation (EBMT), the Supportive Care Group of the European LeukaemiaNet (ELN) and the International Immunocompromised Host Society (ICHS). The objective of the meeting was to develop evidence-based guidelines for the management of bacterial and fungal infections in high-risk immunocompromised adult leukaemia patients and hematopoietic stem cell transplantation recipients. The conference was held on September 30th and October 1st, 2005 in Juan-les-Pins, France and brought together a panel of 59 expert haematologists, oncologists, microbiologists, infectious disease specialists and clinical trialists from across Europe, Israel and Australia. The ECIL1 Guidelines were formulated after lengthy discussion, debate and panel consensus on the findings from a relevant comprehensive literature search, results of a European current practice questionnaire and other international guidelines, specific to each of the six clinical areas examined. The final recommendations, published in the Supplements of this journal as a series of six manuscripts in 2007, were well received by the medical community. The ECIL1 organisers anticipated the need for regular review of these guidelines and the Second ECIL Conference was held in September 2007. Publication of the updated and expanded ECIL2 Guidelines is forthcoming. This paper provides a concise summary of the methodology and main recommendations of the ECIL1 Guidelines.

Entities:  

Mesh:

Year:  2008        PMID: 18707872     DOI: 10.1016/j.ejca.2008.07.008

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  12 in total

1.  Use of antifungal agents in pediatric and adult high-risk areas.

Authors:  E Ramírez; J García-Rodríguez; A M Borobia; J M Ortega; S Lei; A Barrios-Fernández; M Sánchez; A J Carcas; A Herrero; J M de la Puente; J Frías
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-07-01       Impact factor: 3.267

2.  Posaconazole prophylaxis during front-line chemotherapy of acute myeloid leukemia: a single-center, real-life experience.

Authors:  Corrado Girmenia; Anna Maria Frustaci; Giuseppe Gentile; Clara Minotti; Claudio Cartoni; Saveria Capria; Silvia Maria Trisolini; Angela Matturro; Giuseppina Loglisci; Roberto Latagliata; Massimo Breccia; Giovanna Meloni; Giuliana Alimena; Robin Foà; Alessandra Micozzi
Journal:  Haematologica       Date:  2011-11-18       Impact factor: 9.941

Review 3.  A review of infectious complications after haploidentical hematopoietic stem cell transplantations.

Authors:  Erden Atilla; Pinar Ataca Atilla; Sinem Civriz Bozdağ; Taner Demirer
Journal:  Infection       Date:  2017-04-17       Impact factor: 3.553

4.  Polymyxin B, in combination with fluconazole, exerts a potent fungicidal effect.

Authors:  Bing Zhai; Henry Zhou; Liangpeng Yang; Jun Zhang; Kathy Jung; Chou-Zen Giam; Xin Xiang; Xiaorong Lin
Journal:  J Antimicrob Chemother       Date:  2010-02-18       Impact factor: 5.790

5.  De-escalation of antimicrobial treatment in neutropenic patients with severe sepsis: results from an observational study.

Authors:  Djamel Mokart; Géraldine Slehofer; Jérôme Lambert; Antoine Sannini; Laurent Chow-Chine; Jean-Paul Brun; Pierre Berger; Ségolène Duran; Marion Faucher; Jean-Louis Blache; Colombe Saillard; Norbert Vey; Marc Leone
Journal:  Intensive Care Med       Date:  2014-01       Impact factor: 17.440

6.  G-CSF-primed haplo-identical HSCT with intensive immunosuppressive and myelosuppressive treatments does not increase the risk of pre-engraftment bloodstream infection: a multicenter case-control study.

Authors:  Jinhua Ren; Qiaoxian Lin; Weimin Chen; Congmeng Lin; Yuxin Zhang; Cunrong Chen; Shaozhen Chen; Xiaohong Yuan; Ping Chen; Xiaofeng Luo; Yun Lin; Lvying Shen; Mengxian Guo; Qiuru Chen; Min Xiao; Yongquan Chen; Xueqiong Wu; Yanling Zeng; Zhizhe Chen; Xudong Ma; Jianda Hu; Ting Yang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-01-26       Impact factor: 3.267

7.  Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain.

Authors:  Santiago Grau; Rafael de la Cámara; Francisco J Sabater; Isidro Jarque; Enric Carreras; Miguel A Casado; Miguel A Sanz
Journal:  BMC Infect Dis       Date:  2012-04-03       Impact factor: 3.090

8.  Bloodstream infections and mortality-related factors in febrile neutropenic cancer patients.

Authors:  Elif Sahin Horasan; Gulden Ersoz; Anil Tombak; Naci Tiftik; Ali Kaya
Journal:  Med Sci Monit       Date:  2011-05

9.  Antibacterial prophylaxis in neutropenic children with cancer.

Authors:  Angelica Barone
Journal:  Pediatr Rep       Date:  2011-02-24

10.  The strategy of antibiotic use in critically ill neutropenic patients.

Authors:  Matthieu Legrand; Adeline Max; Benoît Schlemmer; Elie Azoulay; Bertrand Gachot
Journal:  Ann Intensive Care       Date:  2011-06-15       Impact factor: 6.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.